New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis […]
35Pharma Announces Clearance of Clinical Trial Application for HS135, Best-in-Class Activin and GDF Inhibitor
Montréal, QC, Canada (Jan 03, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it received a No Objection Letter from Health Canada for its Clinical Trial Application to initiate HS135-001, a Phase 1 study of HS135 in healthy volunteers. “Overactive Activin and GDF signalling is a genetically and clinically validated […]
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
PRINCETON, N.J. & SAN DIEGO–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was […]
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company’s […]
RayzeBio Announces Closing of Upsized $358 Million IPO
SAN DIEGO–(BUSINESS WIRE)–Sep. 19, 2023– RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from […]
Introducing Fierce Biotech’s 2023 Fierce 15 – FOG and RayzeBio
It’s been a tough year for biotech, so how about a little good news? In between all the layoffs, restructurings and last-ditch strategic option hunting, we wanted to take a moment to shine a spotlight on 15 innovative and truly fierce biotechs. Everyone we talk to in the Fierce Biotech universe tells us that science […]
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
SAN DIEGO, August 16, 2023 — Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for AlloNK® (also known as AB-101), in combination with rituximab […]
ImmPACT Bio Announces FDA Clearance of IND Application
Dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and potential to reset immune system No neurotoxicity and only Grade 1 cytokine release syndrome in ongoing UCLA investigator-led study in lymphoma West Hills, Calif., August 15, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) […]
Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform
Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT, Calif. and MENLO PARK, Calif., June 20, 2023 (GLOBE NEWSWIRE) — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a […]
Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer
Proprietary ROVEr™ platform enables design of next-generation radiopharmaceuticals with tunable pharmacokinetic (PK) properties to maximize therapeutic effect and mitigate systemic toxicities Potential for alpha- or beta-emitting radiopharmaceuticals, for clinically validated and novel cancer targets with a wide range of antigen expression Lead program targeting DLL3 for small cell lung cancer and other solid tumors advancing […]
